SNM

RELATED CONTENT

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) announced the creation of the Mars Shot Fund, an initiative to raise $100 million to help pay for research into nuclear medicine, molecular imaging, and therapy.

News | SNMMI

SNMMI Launches Mars Shot Fund for Nuclear Medicine Research

June 14, 2022 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) announced the creation of the Mars Shot ...

June 14, 2022

News | SNMMI

SNMMI elects Munir Ghesani, MD, FACNM, FACR, as President at 2022 ...

June 14, 2022 — Munir Ghesani, MD, FACNM, FACR, chief of nuclear medicine and molecular imaging at Mount Sinai Health ...

June 14, 2022

News | Nuclear Imaging

New ASNC/SNMMI Training Course Helps Physicians Meet U.S. Requirements ...

April 13, 2022 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the American Society of Nuclear ...

April 13, 2022

Quantitative analysis of pre-treatment PSMA PET/CT in a patient undergoing treatment with ¹⁷⁷Lutetium-PSMA-617/NOX66. Post-treatment PSMA PET/CT demonstrates reduced tumor volume and PSMA intensity. Images created by S Pathmanandavel and L Emmett, St Vincent's Hospital, Sydney, Australia.

News | PET-CT

New Radionuclide Combination Therapy Safe and Effective in Metastatic ...

April 11, 2022 — A novel nuclear medicine combination therapy has been proven safe and effective in men with heavily pre ...

April 11, 2022

With today’s U.S. Food and Drug Administration (FDA) approval of 177Lu-PSMA-617—a radiopharmaceutical therapy to treat metastatic castration-resistant prostate cancer (mCRPC)—the Society of Nuclear Medicine and Molecular Imaging (SNMMI) celebrates one of the greatest success stories in nuclear medicine history.

News | Prostate Cancer

SNMMI Applauds FDA Approval of New Metastatic Prostate Cancer ...

March 23, 2022 — With today’s U.S. Food and Drug Administration (FDA) approval of ¹⁷⁷Lu-PSMA-617—a radiopharmaceutical ...

March 23, 2022

F-18 FDG PET in COVID-19–related CNS disorders: Principal components analysis of spatial covariance pattern (first row) and statistical parametric mapping analysis of metabolic group differences (second to fifth rows) in patients with COVID-19–related encephalopathy, patients with post-COVID-19 syndrome, and patients with post-COVID-19 syndrome and hyposmia compared to healthy controls (n=13). Image Created by PT Meyer, S Hellwig, G Blazhenets and JA Hosp, Medical Center – University of Freiburg, Germany.

News | Coronavirus (COVID-19)

Molecular Imaging Uncovers Effects of COVID-19 on the Brain

March 23, 2022 — A significant number of COVID-19 neurological complications— such as fatigue, headache, and cognitive ...

March 23, 2022

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has named Stanford Health Care and the Dana-Farber Brigham Cancer Center as its first two designated Radiopharmaceutical Therapy Centers of Excellence.

News | SNMMI

SNMMI designates first Radiopharmaceutical Therapy Centers of ...

March 16, 2022 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has named Stanford Health Care and the Da ...

March 16, 2022

The Task Force members have recently observed an unusual imaging pattern on FDG PET/CT or FDG PET/MR that may be due to COVID-19 infection.

News | Coronavirus (COVID-19)

SNMMI Task Force Reports Possible Effect of Omicron Infection on FDG ...

January 17, 2022 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) issued a statement on Jan. 14 regarding ...

January 17, 2022

The Council on Radionuclides and Radiopharmaceuticals, Inc. (CORAR), along with physicians and patient organizations, supports the introduction of H.R. 4479, the “Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021” by Congressmen Scott Peters (D-CA), Bobby Rush (D-IL), Neal Dunn (R-FL) and Greg Murphy (R-NC).

News | Nuclear Imaging

Council on Radionuclides and Radiopharmaceuticals Supports the FIND ...

August 4, 2021 — The Council on Radionuclides and Radiopharmaceuticals, Inc. (CORAR), along with physicians and patient ...

August 04, 2021

Feature | Molecular Imaging | Melinda Taschetta-Millane

Highlights from SNMMI

I recently attended the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in San Diego. This year’s meeting included a celebration of the 40th anniversary of FDG, a radiopharmaceutical used in the medical imaging modality positron emission tomography (PET) that has had a pervasive impact on molecular imaging. At the opening plenary session, the Henry Wagner Lecture was given by Joanna Fowler, Ph.D., Brookhaven National Laboratory, on “Designing and Synthesizing FDG for the First Human Studies in 1976.” Signage throughout the convention center featured FDG pioneers and quotes on FDG by past presidents.

July 06, 2016